Clinical Trials | January 08, 2026
Alumis reports breakthrough Phase 3 results for oral psoriasis therapy
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline
Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies
Imsidolimab, an IgG4 IL-36 receptor antagonist, works by inhibiting IL-36 receptor signaling, directly addressing the deficiency in the IL-36RA regulator common in GPP patients
Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials
The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara
The drug exhibited greater treatment persistence and control of moderate-to-severe PsO symptoms compared to secukinumab and ixekizumab
EC grants conditional marketing authorization based on the EFFISAYIL trial
CHMP positive opinion is based on evidence from the EFFISAYIL trial, the largest clinical trial in
Spesolimab is a monoclonal antibody that inhibits interleukin-36 (IL-36) signaling and is the first treatment specifically approved for the treatment of generalized pustular psoriasis flares
Subscribe To Our Newsletter & Stay Updated
